Solid-State Analysis · GMP-compliant particle and solid-state characterization

We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.

Partnering with Kymos Group on our preclinical program for our first asset has been invaluable. Their team brought deep analytical expertise and ensured that biodistribution and histology assessments were conducted to the highest scientific and regulatory standards. Thanks to their responsiveness and commitment, we generated high-quality data that strengthened our preclinical package. We look forward to continuing our collaboration as we advance this innovative therapy into the clinic.

We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.

Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.

Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.

I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.

Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.